ClinicalTrials.gg
CompletedNCT05077436Updated Aug 17, 2022

Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

A Phase 1 interventional study of Vamifeport Formulation 1 and Vamifeport Formulation 2 in Healthy, sponsored by Vifor (International) Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-17.

Sponsored by Vifor (International) Inc. (part of CSL Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Two different vamifeport oral formulations will be administered in fed and fasted state to assess the vamifeport food-drug interaction and to assess the relative bioavailability (the proportion of drug entering the circulation) of 2 different vamifeport oral formulations in healthy adult participants.

Participants will be randomly allocated to one of four treatment sequences, with four dosing periods each, where different combinations of both formulations will be administered following fasted and fed state.

The total study duration for each participant is up to 7 weeks and 4 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Vifor (International) Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.

First submitted before Vifor (International) Inc. became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participant. Healthy status defined by the Investigator.
  • A body weight between 50 and 100 kg inclusive at screening.
  • Non-smokers, or former smokers.
  • Both female and male participants must agree to comply with the requirements for the study.
  • Ability to understand the requirements of the study and abide by the study restrictions, and agreement to return for the required assessments.

Exclusion criteria

Exclusion Criteria:

  • History of gastrointestinal, cardiovascular, musculoskeletal, endocrine, neurological, hematological, psychiatric, renal, hepatic, bronchopulmonary, allergic or lipid metabolism disorders, cancer, or drug .
  • Any clinically relevant abnormal 12-lead finding during screening or prior to randomization.
  • A clinically relevant history of drug or alcohol misuse or abuse within 2 years prior to screening.
  • Positive qualitative or semi-quantitative test for drugs of abuse positive cotinine screen (used to detect recent nicotine use), or alcohol breath test at screening (Visit 1) or Study Day -1 (Visit 2). Use of any of these agents will be not permitted during study participation.
  • Strenuous physical exercise within the 1 week prior to Visit 2/Study Day -1 admission, and until completion of safety follow-up assessments are completed.
  • Female participants who are pregnant or breastfeeding.
  • Any concomitant medication (including herbal remedies and vitamins) taken within 2 weeks prior to Visit 2.
  • Concomitant use of hormonal (contraception associated with inhibition of ovulation), which are metabolized through cytochrome P450 (CYP) 3A4.
  • Any other drug.
  • Blood draw or blood donation of ≥20 to \<200 ml within 2 weeks, ≥200 to \<400 ml within 4 weeks, or ≥400 ml within 12 weeks (male) or within 16 weeks (female) prior to Visit 2.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fasted state receive Vamifeport Formulation 1 * Day 5: Participants in fed state receive Vamifeport Formulation 1 * Day 9: Participants in fed state receive Vamifeport Formulation 2 * Day 13: Participants in fasted state receive Vamifeport Formulation 2

    Drug: Vamifeport Formulation 1 · Drug: Vamifeport Formulation 2

  • Experimental
    Sequence 2

    Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fed state receive Vamifeport Formulation 1 * Day 5: Participants in fasted state receive Vamifeport Formulation 2 * Day 9: Participants in fasted state receive Vamifeport Formulation 1 * Day 13: Participants in fed state receive Vamifeport Formulation 2

    Drug: Vamifeport Formulation 1 · Drug: Vamifeport Formulation 2

  • Experimental
    Sequence 3

    Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fasted state receive Vamifeport Formulation 2 * Day 5: Participants in fed state receive Vamifeport Formulation 2 * Day 9: Participants in fed state receive Vamifeport Formulation 1 * Day 13: Participants in fasted state receive Vamifeport Formulation 1

    Drug: Vamifeport Formulation 1 · Drug: Vamifeport Formulation 2

  • Experimental
    Sequence 4

    Participants receive a single dose of study drug, every 4 days: * Day 1: Participants in fed state receive Vamifeport Formulation 2 * Day 5: Participants in fasted state receive Vamifeport Formulation 1 * Day 9: Participants in fasted state receive Vamifeport Formulation 2 * Day 13: Participants in fed state receive Vamifeport Formulation 1

    Drug: Vamifeport Formulation 1 · Drug: Vamifeport Formulation 2

Interventions

  • DrugVamifeport Formulation 1

    Vamifeport Formulation 1 is available as 60 mg oral capsules

  • DrugVamifeport Formulation 2

    Vamifeport Formulation 2 is available as 60 mg oral capsules

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-last) of vamifeport

    Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

  2. Area under the plasma concentration versus time curve from time 0 extrapolated to infinite time (AUC0-infinity) of vamifeport

    Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

  3. Maximum observed concentration (Cmax) of vamifeport

    Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

Secondary outcomes

  1. Time of maximum vamifeport plasma concentration (Tmax)

    Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

  2. Apparent terminal disposition phase half-life (tl/2)

    Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

  3. Apparent terminal disposition phase rate constant

    Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

  4. Apparent total clearance

    Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

  5. Apparent volume of distribution during the terminal disposition phase

    Time frame: Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose

07

Study locations

1 site
  • Labcorp Clinical Research Unit Ltd.
    Leeds, LS2 9LH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Oct 14, 2021
StartActual
Oct 14, 2021
Primary completionActual
Dec 29, 2021
CompletionActual
Jan 5, 2022
Last update
Aug 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05077436
Responsible party
Sponsor
First posted
Oct 14, 2021
Start date
Oct 14, 2021
Primary completion
Dec 29, 2021
Completion
Jan 5, 2022
Last update
Aug 17, 2022

Study contacts

Peter Szecsödy, MD
study director · Clinical Research Director

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion